title: Association of plasma intermedin levels with progression and metastasis in men after radical prostatectomy for localized prostatic cancer.
abstract: BACKGROUND
  Adrenomedullin levels in the peripheral blood are associated with prognosis of some cancers. Intermedin is structural similarities to adrenomedullin.
  
  
  OBJECTIVE
  The current study aimed to investigate the prognostic value of plasma intermedin levels for progression and distant metastasis in prostate cancers.
  
  
  METHODS
  This study included 218 patients undergoing radical prostatectomy for localized prostatic cancer and 218 age-matched healthy men. Plasma intermedin levels were measured using radioimmunoassay. The relationships between plasma intermedin levels and 5-year progression and 5-year distant metastasis were evaluated using a multivariate analysis.
  
  
  RESULTS
  Plasma intermedin levels were markedly higher in all patients than in healthy men. Patients with Gleason score ≥ 7, tumor node metastasis stage T2, organ unconfined, present extra-prostatic extension, seminal vesicle invasion or positive lymph node had higher intermedin levels. Intermedin was identified as a prognostic predictor for 5-year progression and 5-year metastasis. Under receiver operating characteristic curves, intermedin had high predictive values for 5-year progression and 5-year metastasis.
  
  
  CONCLUSIONS
  Elevated plasma intermedin levels are independently associated with long-term recurrence and distant metastasis of prostate cancer and intermedin has potential to be a prognostic predictive biomarker for prostate cancer.
authors.forename: Xu-Liang
authors.initials: XL
authors.lastname: Wang
authors.forename: Yu-Yong
authors.initials: YY
authors.lastname: Wang
authors.forename: Hua-Dong
authors.initials: HD
authors.lastname: He
authors.forename: Xi
authors.initials: X
authors.lastname: Xie
authors.forename: Zhi-Jian
authors.initials: ZJ
authors.lastname: Yu
authors.forename: Yu-Ming
authors.initials: YM
authors.lastname: Pan
mesh_terms: D000230:Adenocarcinoma / Q000378:metabolism / Q000556:secondary* / Q000601:surgery; D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D016022:Case-Control Studies; D018450:Disease Progression; D005500:Follow-Up Studies; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D009364:Neoplasm Recurrence, Local / Q000378:metabolism / Q000473:pathology* / Q000601:surgery; D009367:Neoplasm Staging; D036361:Peptide Hormones / Q000097:blood*; D011379:Prognosis; D011467:Prostate / Q000378:metabolism / Q000473:pathology*; D017430:Prostate-Specific Antigen / Q000097:blood; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000378:metabolism / Q000473:pathology* / Q000601:surgery; D011863:Radioimmunoassay
chemical_list: C484330:ADM2 protein, human; D014408:Biomarkers, Tumor; D036361:Peptide Hormones; D017430:Prostate-Specific Antigen
keywords: Prostate cancer; intermedin; metastasis; recurrence